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The relationship between glucose and lipid metabolism has
been of signiﬁcant interest in understanding the pathogenesis
of obesity-induced insulin resistance. To gain insight into this
metabolic paradigm, we explored the potential interplay between
cellular glucose ﬂux and lipid-induced metabolic dysfunction
within skeletal muscle. Here, we show that palmitate (PA)-
induced insulin resistance and proinﬂammation in muscle cells,
which is associated with reduced mitochondrial integrity and
oxidative capacity, can be attenuated under conditions of glucose
withdrawal or glycolytic inhibition using 2-deoxyglucose (2DG).
Importantly, these glucopenic-driven improvements coincide
with the preservation of mitochondrial function and are de-
pendent on PA oxidation, which becomes markedly enhanced
in the absence of glucose. Intriguingly, despite its ability to
upregulate mitochondrial PA oxidation, glucose withdrawal did
not attenuate PA-induced increases in total intramyocellular
diacylglycerol and ceramide. Furthermore, consistent with our
ﬁndings in cultured muscle cells, we also report enhanced insulin
sensitivity and reduced proinﬂammatory tone in soleus muscle
from obese Zucker rats fed a 2DG-supplemented diet. Notably,
this improved metabolic status after 2DG dietary intervention is
associated with markedly reduced plasma free fatty acids.
Collectively, our data highlight the key role that mitochondrial
substrate availability plays in lipid-induced metabolic dysregula-
tion both in vitro and in vivo. Diabetes 62:3426–3436, 2013
There is signiﬁcant evidence in the literaturelinking elevation in free fatty acid (FFA) levelswith development of peripheral insulin resis-tance and its associated metabolic perturbations,
including impaired glucose uptake (1). However, as yet,
there is no uniﬁed view that adequately explains how these
pathophysiological events develop. Randle et al. (2) ﬁrst
postulated that increased mitochondrial fatty acid oxidation
(associated with FFA oversupply) may impair glucose
uptake and utilization via metabolite-induced allosteric
inhibition of key glycolytic enzymes. Speciﬁcally, inhibi-
tion of pyruvate dehydrogenase and phosphofructokinase
by acetyl CoA and citrate generated from excessive FFA
oxidation would culminate in accumulation of glucose-6-
phosphate (G6P) that, in turn, would promote allosteric
inhibition of hexokinase with a concomitant reduction in
glucose uptake. However, the concept that suppressed
glycolytic ﬂux underlies lipid-induced metabolic dysfunc-
tion has been challenged by an alternative school of thought
implicating ectopic accumulation of lipids as the primary
cause of insulin resistance in skeletal muscle (3,4). In
particular, lipid oversupply in the form of excess saturated
fatty acids including palmitate (PA) (C16:0) promotes
intramyocellular accumulation of bioactive lipids such as
diacylglycerol (DAG) and ceramide. These lipids have been
implicated strongly in the development of insulin resistance
via their inhibitory effects on proximal insulin signaling, and
as such, their effects may depend or be further accentuated
by glucose overloading (i.e., glucolipotoxicity). Notably,
activated DAG-sensitive protein kinase C (PKC) isoforms
suppress insulin action via elevated serine phosphoryla-
tion of insulin receptor substrates, such as insulin receptor
substrate (IRS)-1 (5,6), whereas ceramide induces a tar-
geted loss in activation of the serine/threonine kinase, Akt,
by insulin (7). Both IRS and Akt serve as critical compo-
nents of the insulin signaling cascade, and so their dysre-
gulation impairs key processes under the control of insulin,
including glucose uptake and glycogen synthesis.
In accordance with evidence supporting a role for lip-
otoxic intermediates in the pathogenesis of insulin resistance,
a number of studies have also explored the relationship
between insulin sensitivity and mitochondrial function.
Importantly, various indicators of impaired mitochondrial
capacity have been reported in skeletal muscle from insulin-
resistant or obese human subjects including, for exam-
ple, a reduction in the activity or expression of carnitine
palmitoyltransferase-1, which mediates mitochondrial fatty
acid uptake, and that of various oxidative enzymes and
respiratory chain components coinciding with suppressed
ATP synthesis (8–13). Furthermore, obesity-induced reduc-
tions in peroxisome proliferator–activated receptor g
coactivator (PGC)-1a, a key transcriptional coordinator of
mitochondrial biogenesis, and elevated expression of mus-
cle nuclear factor kB (NF-kB)-dependent proinﬂammatory
genes (e.g., interleukin-6 [IL-6], tumor necrosis factor-a),
may contribute signiﬁcantly to FFA-induced mitochondrial
dysfunction and insulin resistance (12,14–18). Collectively,
these observations support the idea that mitochondrial
dysfunction (associated with lipid oversupply) may re-
strict FFA oxidation and promote their greater parti-
tioning into bioactive lipid intermediates, such as
ceramide and DAG, that negatively regulate insulin action.
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ORIGINAL ARTICLE
Herein, given the current focus on fuel substrate–derived
metabolites, lipotoxic intermediates, and mitochondrial en-
ergetics, we sought to explore their interrelationship and
involvement in obesity and FFA-induced metabolic dys-
regulation by assessing the effects of restricting glucose
utilization both in vitro and in vivo. Together, our data
underscore the important role that mitochondrial sub-
strate overload, in particular with respect to glucose and
fatty acid provision, plays in the development of lipid-
mediated insulin resistance and associated proinﬂammatory
cytokine production in skeletal muscle.
RESEARCH DESIGN AND METHODS
Ten-week-old male obese (fa/fa) and lean (Fa/fa) Zucker rats obtained from
Harlan UK (Oxon, U.K.) were maintained on a 12-h light/dark cycle and fed ad
libitum a standard or 2-deoxyglucose (2DG) (0.4% w/w) supplemented chow
diet for 28 days. The 2DG diet was prepared by pulverizing standard chow
pellets and reconstituting with 2DG powder. Body weights and food intake
were monitored twice weekly. After the 28-day dietary regimen, animals were
fasted overnight (16 h) and subsequently anesthetized by injection of sodium
pentobarbitone (60 mg/kg i.p.). Blood sampling, careful excision, and rapid
freezing in liquid nitrogen of soleus from one hindlimb were then performed
prior to administration of insulin (10 units/kg i.v., Actrapid; Novo Nordisk,
Bagsværd, Denmark). Five minutes post–insulin administration, soleus muscle
from the contralateral hindlimb was removed and immediately frozen in liquid
nitrogen for storage at 280°C. All animal procedures complied with the U.K.
Animal Scientiﬁc Procedures Act.
Muscle cell culture, cell treatments, and analysis. Methods used for cul-
turing and treating rat (L6) and primary human myotubes with PA and their
preparation for immunoblotting, RNA extraction, conventional RT-PCR and
real-time quantitative (qPCR) analysis, PA oxidation, and whole-cell oxygen
consumption and analysis of intramyocellular DAG and ceramide have pre-
viously been described (19–22) or are described in the Supplementary Data.
Measurement of intracellular metabolites. L6 myotubes were incubated
with 0.5 mmol/L PA in the absence or presence of 5 mmol/L glucose as indicated
in the appropriate ﬁgure legends. After treatment, cells were lysed in ice-cold
chloroform/methanol/water (1:3:1) and resulting samples analyzed by liquid
chromatography–mass spectrometry (LCMS) as previously described (23).
Analysis of LCMS data was performed using MzMatch (24) and IDEOM (23)
software, with metabolites conﬁrmed by mass and retention time analysis
being matched against authentic standards or classiﬁed as putative, based on
mass, predicted retention time, and biochemical reference (23).
Determination of blood and tissue biochemistry. Plasma FFA concentra-
tion was measured using the EnzyChrom Free Fatty Acid Assay Kit from
BioAssay Systems (Hayward, CA). Triglyceride concentration in blood plasma
was determined using the Triglyceride Assay kit from Cayman Chemical (Ann
Arbor, MI). Circulating blood glucose levels were measured using an Alpha-
TRAK Blood Glucose Monitoring System (Abbott Laboratories).
Statistical analyses. For multiple comparisons, statistical analysis was per-
formed using one-way ANOVA or a t test where appropriate. Data analysis was
performed using GraphPad Prism software and considered statistically sig-
niﬁcant at P values ,0.05.
RESULTS
Effects of PA and glucose availability on Akt-directed
insulin signaling. Sustained (16 h) PA overprovision
caused a substantial reduction in the insulin-dependent
phosphorylation/activation of Akt and that of forkhead box
O3 (FOXO3a) and glycogen synthase kinase-3 a/b; both
established Akt targets in L6 myotubes (Fig. 1A). To de-
termine whether this reduced insulin signaling capacity
was a consequence of substrate competition, we in-
vestigated the effects of incubating myotubes with PA for
16 h in 1) glucose-free media, 2) glucose-free media to
which 2DG (a nonmetabolizable glucose analog and gly-
colytic inhibitor) was added as a glucose substitute, or 3)
glucose-containing media to which 2DG was added as
a competitive glucose supplement. This strategy revealed
that while Akt phosphorylation by insulin was severely
blunted by PA when glucose was present (Fig. 1B [compare
lanes 1 and 2]), this inhibition was not detected in myotubes
incubated with PA in the absence of glucose or when
glucose had been substituted or media cosupplemented
with 2DG (Fig. 1B [compare lanes 4 and 8 with 2]). In line
with the ability to restrain the insulin-desensitizing effect
of PA upon glucose withdrawal or 2DG provision, phos-
phorylation of FOXO3a and glycogen synthase kinase-3
a/b was also enhanced (Fig. 1B). This enhancement was
not just restricted to proximal insulin signaling events but
was also evident by changes in hexokinase II gene ex-
pression, which represents a more distal insulin-regulated
response (Fig. 1C). Since the insulin-desensitizing effects
of PA on Akt-directed insulin signaling were potently re-
pressed in the absence of glucose, we assessed whether
we could deﬁne a threshold glucose concentration at which
glucolipotoxicity was no longer evident. Figure 1D shows
that 0.5 mmol/L PA induced a signiﬁcant reduction in
insulin-dependent Akt phosphorylation when cells were
incubated in the presence of glucose at concentrations
.0.2 mmol/L.
To exclude the possibility that the insulin-sensitizing
effect conferred by limiting glucose availability/metabolism
may be a phenomenon restricted to rat skeletal mus-
cle cells, Fig. 1E shows that primary human skeletal
myotubes exposed to PA also exhibit signiﬁcant re-
duction in Akt phosphorylation, which was antagonized
by glucose deprivation.
It is important to stress that the reduction in Akt phos-
phorylation that we observe in muscle cells after incuba-
tion with PA (Fig. 1) is not restricted to this fatty acid
alone. Indeed, exposure of L6 myotubes to stearate (a
C18:0 saturated fatty acid) or to a fatty acid mixture
comprising PA, stearate, oleate, and palmitoleate (at con-
centrations found in plasma of obese, insulin resistant
rodents) promotes a loss in insulin-dependent Akt phos-
phorylation, which, in both instances, can be attenuated if
muscle cells are held in glucose-free or 2DG-supplemented
media (Supplementary Fig. 1).
Effect of PA and glucose availability on proinﬂammatory
signaling. Sustained myotube exposure to PA also stimulates
NF-kB signaling, which depends critically upon upstream ac-
tivation of the mitogen-activated protein kinase (extracellular
signal–related kinase [ERK]) pathway (19). Figure 2A shows
that PA induces a dose-dependent activation of ERK1/2 and
IkB kinase (IKK) a/b with concomitant loss of inhibitor of kB
(IkB) a. However, this PA-induced activation of ERK and
IkBa loss were attenuated in myotubes maintained in glucose-
free media (Fig. 2B and C) or when either glucose was
substituted with 2DG or this glycolytic inhibitor was added to
glucose-containing media (Fig. 2C [compare lanes 6 and 8
with lane 2]). However, unlike Akt activation (Fig. 1C), the
loss of this protein in response to PA was only abrogated
when glucose was completely absent from the media. Con-
sistent with the stimulation that PA promotes in NF-kB sig-
naling when glucose is available, PA induced robust increases
in the expression of two NF-kB target genes: IL-6 and cyto-
kine-induced neutrophil chemoattractant-1 (CINC-1) (the rat
homolog of IL-8), which was not seen in myotubes deprived of
glucose (Fig. 2E and F). These ﬁndings were replicated in
primary human myotubes (Fig. 2G).
Effects of PA and glucose availability upon intramyo-
cellular DAG and ceramides. PA-induced increases in
intramyocellular DAG and ceramide have been shown to
impair IRS-1 and Akt activation (6,25,26). The ability to
restrain the insulin-desensitizing effect of PA when glu-
cose is limiting may be linked to a reduction in PA-driven
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FIG. 1. Limiting glucose availability or its metabolism antagonizes PA-induced insulin resistance in L6 myotubes. A and B: L6 myotubes were
treated with 0.5 mmol/L PA for 16 h in the absence or presence of 5 mmol/L D-glucose with or without 5 mmol/L 2DG as indicated prior to stim-
ulation with insulin (20 nmol/L for 10 min). Resulting cell lysates were analyzed by immunoblotting using the antibodies indicated. *P < 0.05
between bars indicated or vs. non–PA treated. Data values presented as mean 6 SEM, n = 3. C: L6 myotubes were incubated with 0.5 mmol/L PA in
the absence or presence of 5 mmol/L glucose for a total of 16 h. For the ﬁnal 4 h, cells were treated with 100 nmol/L insulin or vehicle control prior
to extraction of total cellular RNA. Hexokinase II (HKII) mRNA expression relative to the internal control cyclophilin was subsequently
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accumulation of DAG and ceramides. However, Fig. 3A and
B shows that while DAG and ceramides were increased by
more than twofold when myotubes were incubated with PA
in glucose-containing media, glucose withdrawal or its sub-
stitution with 2DG had no impact on the accumulation of
either lipid. Our liquid chromatography–mass spectrometry
analysis permits quantiﬁcation of multiple DAGs and
ceramides and reveals that while most are elevated in re-
sponse to PA, glucose withdrawal or glycolytic inhibition
with 2-DG only affected accumulation of a few select
DAG and ceramide species (Supplementary Fig. 2 [DAGs:
C18:0/C18:0, C18:1/C81:1] and Supplementary Fig. 3 [cer-
amide: C14:0, C18:1]). It is possible that under these circum-
stances, the lipotoxic effects associated with DAG and
ceramide are negated by their generation in membrane com-
partments spatially segregated from those in which insulin
signaling is initiated. To test this possibility, we incubated
myotubes with increasing concentrations of C2 ceramide,
a cell-permeable ceramide analog whose cellular distribution
is unlikely to be constrained to speciﬁc membrane pools.
Figure 3C shows that regardless of glucose availability, Akt
activation by insulin was inhibited by C2 ceramide.
determined by RT-PCR analysis. Relative band intensity values presented are the mean 6 SEM from three independent experiments. *Signiﬁcant
change (P < 0.05) from the untreated control (lane 1). D: L6 myotubes were incubated with 0.5 mmol/L PA for 16 h in the presence of different
concentrations of glucose as indicated prior to stimulation with insulin (20 nmol/L for 10 min). Resulting cell lysates were immunoblotted using the
antibodies shown. Relative band intensity values presented are the mean 6 SEM from three independent experiments. *Signiﬁcant change (P <
0.05) from the insulin/5 mmol/L glucose bar value (lane 1). E: Representative immunoblot for total and phosphorylated Ser473 Akt in primary
human skeletal muscle myotubes treated with 0.25 mmol/L PA for 22 h in media containing or lacking 5 mmol/L D-glucose prior to stimulation with
insulin (100 nmol/L for 10 min). Data values presented as mean 6 SEM, n = 4. (*P < 0.05 between the indicated bars.) ND, no difference.
FIG. 2. Limiting glucose availability or its utilization antagonizes PA-induced inﬂammation in L6 myotubes. A–C: L6 myotubes were treated with
different concentrations of PA (A) or 0.5 mmol/L PA (B and C) for 16 h in media containing or lacking either 5 mmol/L D-glucose or 5 mmol/L 2DG
as indicated. Resulting cell lysates were immunoblotted using the antibodies indicated. D: L6 myotubes were incubated with 0.5 mmol/L PA for 16 h
in the presence of different concentrations of glucose as indicated. Resulting cell lysates were immunoblotted using the antibodies shown. Relative
band intensity values presented are the mean 6 SEM from three independent experiments. *Signiﬁcant change (P < 0.05) from the untreated
control (lane 1). E–G: L6 myotubes (E and F) and human primary skeletal muscle myotubes (G) were treated with 0.5 mmol/L (for 16 h) or 0.25
mmol/L (for 22 h) PA, respectively, in the absence or presence of 5 mmol/L D-glucose. After cell treatments, total RNA was extracted and used to
determine relative mRNA expression of IL-6 and CINC-1 to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or 28S rRNA by qPCR as in-
dicated. Data values presented are mean6 SEM (n = 3 for L6 myotubes; n = 4 for human primary skeletal muscle myotubes). *P< 0.05 between the
indicated bars.
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Effects of substrate availability on mitochondrial
function. Insulin resistance and heightened proinﬂammatory
signaling may be a consequence of mitochondrial dys-
function induced by substrate overload. Figure 4A shows
that cellular respiration fell signiﬁcantly (;50%) when
myotubes were incubated with PA and glucose. This re-
duced aerobic capacity was not observed when cells were
exposed to PA alone or when glucose was substituted with
2DG. In line with these observations, analysis of ATP and
ADP revealed that the ATP-to-ADP ratio fell signiﬁcantly
from 16.2 6 1.2 to 8.1 6 1.0 in myotubes incubated with
PA and glucose, whereas this ratio was unaltered in cells
exposed to PA alone (not shown). The ability to maintain
cellular respiration in myotubes treated with just PA implies
that cells may oxidize PA more efﬁciently. Indeed, PA oxida-
tion was approximately threefold greater than in myotubes
incubated with PA and glucose together (Fig. 4B). This
increase in PA oxidation was sensitive to 2-bromopalmi-
tate and etomoxir, two carnitine palmitoyltransferase-1
inhibitors (27). To assess whether the reduced respiratory
rate associated with PA and glucose overload is a conse-
quence of impaired mitochondrial integrity/function, we
monitored the abundance of PGC-1a, cytochrome c oxidase
subunit IV (COXIV), and succinate dehydrogenase (SDHA).
These proteins were reduced substantially in cells treated
with PA and glucose but maintained when either nutrient
was present alone or when glucose metabolism was
inhibited by 2DG (Fig. 4C).
Consistent with the reduction in SDHA associated with
glucose/PA overload (Fig. 4C), we observed a signiﬁcant
decline in fumarate, the product of succinate oxidation by
SDHA, and malate, which is generated from hydration of
fumarate. Intriguingly, both metabolites were signiﬁcantly
elevated in myotubes incubated with PA alone, most likely
due to increased anaplerotic ﬂux via reactions contributing
to their maintenance. Since glucose withdrawal or glycolytic
inhibition is protective against the insulin-desensitizing and
proinﬂammatory effects of PA, we hypothesized that this
may depend on using PA as fuel when glucose supply is
restricted. Indeed, inhibiting mitochondrial PA uptake using
2-bromopalmitate induced a dose-dependent reduction in
insulin-stimulated Akt phosphorylation and IkBa loss in
response to PA despite the absence of glucose (Fig. 4E).
The ability to sustain PA oxidation in the absence of
glucose requires maintaining levels of key tricarboxylic
acid (TCA) cycle metabolites such as oxaloacetate (OAA)
via anaplerotic reactions like that catalyzed by pyruvate
carboxylase. As anticipated, cells incubated with PA alone
exhibit a dramatic reduction in glycolytic intermediates,
such as G6P and glyceraldehyde 3-phosphate (Fig. 5A).
Intriguingly, however, despite withdrawing glucose the
abundance of pyruvate (the end product of glycolysis) was
maintained in myotubes treated with PA alone (Fig. 5B).
We postulated that irreversible carboxylation of pyruvate
by pyruvate carboxylase may help sustain mitochondrial
anaplerosis. To test this hypothesis, the effect of phenyl-
acetic acid (PAC), a pyruvate carboxylase inhibitor, was
assessed in myotubes treated with PA in the absence and
presence of glucose. Figure 5C and D show that while the
insulin-desensitizing and proinﬂammatory effect of PA is
attenuated by glucose withdrawal, this protective effect was
progressively eroded by PAC in a dose-dependent manner.
Since pyruvate would normally be generated via gly-
colysis, it is likely that in the absence of glucose it is
generated by transamination of alanine prior to being
channeled into mitochondria for OAA synthesis by pyruvate
carboxylase. Figure 5E and F shows that aminooxyacetate,
a transaminase inhibitor (28), antagonized the protective
effect conferred by glucose withdrawal upon Akt phos-
phorylation and IkBa.
Effects of 2DG on metabolic homeostasis in obese
Zucker (fa/fa) rats. To validate whether restricting
skeletal muscle glucose utilization confers similar insulin-
sensitizing and anti-inﬂammatory effects in vivo, the effect
of a glucopenic dietary intervention in an appropriate an-
imal model was investigated. Obese male Zucker (fa/fa)
rats and their lean littermates were placed on either a
FIG. 3. Limiting glucose availability does not prevent PA-induced
ceramide and DAG accumulation in L6 myotubes. A and B: Total cellular
DAG (A) and ceramide (B) content in L6 myotubes after treatment
with 0.5 mmol/L PA (or vehicle control) for 16 h in the absence or
presence of 5 mmol/L D-glucose or 5 mmol/L 2DG as indicated. C: L6
myotubes were treated with different concentrations of C2 ceramide for
2 h in serum-free media containing or lacking 5 mmol/L D-glucose prior to
insulin stimulation (20 nmol/L for 10 min). Resulting cell lysates were
immunoblotted for total and phosphorylated Ser473 Akt. Data are pre-
sented as mean 6 SEM from three independent experiments.
SUBSTRATE OVERLOAD AND MITOCHONDRIAL DYSFUNCTION
3430 DIABETES, VOL. 62, OCTOBER 2013 diabetes.diabetesjournals.org
normal chow diet or one supplemented with 2DG for 28
days. Figure 6A shows that lean and obese rats on the 2DG
diet gain considerably less weight than their respective
counterparts fed the normal chow diet, although the effect
was far greater (approximately threefold) in obese than
lean animals (Supplementary Table 1). Although weight gain
in the lean animals on the 2DG diet was consistently lower
at each measurement point over the 28-day period compared
with lean controls fed the standard diet, the difference
between these groups (unlike the obese animals) fell short
of being signiﬁcant. Despite no enforced restriction on
how much food animals could eat, obese rats consumed
marginally less on the 2DG diet, whereas no differences
were observed in food intake in lean animals (Fig. 6B).
Effects of 2DG upon plasma glucose, FFAs, triglyceride,
epididymal fat pad, and soleus mass. Figure 6C shows
that fasting plasma glucose remained signiﬁcantly higher in
obese compared with lean animals reﬂecting the fact that the
obese animals used in our study are severely glucose in-
tolerant and insulin resistant. Intake of 2DG induced a
modest reduction in circulating glucose in both lean and
obese rats (by ;18%). This ﬁnding is consistent with the
known glucopenic effect induced by 2DG consumption (29).
Obese Zucker rats are characteristically hyperlipidemic. In
line with this, plasma triglyceride was elevated by ;11-fold
and FFAs by ;2.5-fold compared with their lean littermates
(Fig. 6D and E). Although 2DG intake induced a slight re-
duction in plasma triglyceride in obese animals, this was not
signiﬁcant (Fig. 6D). In contrast, 2DG consumption induced
a profound reduction in plasma FFAs in obese rats (Fig. 6E),
which occurs alongside a modest but signiﬁcant fall in epi-
didymal fat mass (Fig. 6F). Similar reductions were not ap-
parent in lean animals fed 2DG. No notable changes in soleus
mass between animals fed the standard chow or 2DG diets
were observed (data not shown).
2DG intake improves insulin signaling and reduces
inﬂammatory tone in muscle of obese rats. Figure 7A
shows that there were no detectable differences in the
insulin-dependent phosphorylation of Akt in solei from
three lean animals fed either the standard or the 2DG diet.
FIG. 4. Improvements in mitochondrial function in response to restricted glucose availability or its utilization contributes to enhanced insulin
sensitivity and reduced proinﬂammatory signaling. A: L6 myotubes were incubated with 0.5 mmol/L PA (or vehicle control) for 16 h in media
supplemented with or without 5 mmol/L D-glucose or 5 mmol/L 2DG as shown. Oxygen consumption rates were subsequently measured as described
in Supplementary Data. *P < 0.05 vs. non–PA treated. B: L6 myotubes were incubated in the absence or presence of 5 mmol/L D-glucose for 3 h
in the absence or presence of 2-bromopalmitate (2-BrPA) (100 mmol/L) or etomoxir (100 mmol/L), as indicated, prior to determining the rate
of [3H]PA oxidation. *P < 0.05 compared with glucose-containing treatment. C: Representative immunoblot for PGC-1a, COXIV, SDHA, and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in L6 myotubes treated with 0.5 mmol/L PA (or vehicle control) for 16 h in the absence or
presence of 5 mmol/L D-glucose or 5 mmol/L 2DG. D: Fumarate and malate content in L6 myotubes after treatment with 0.5 mmol/L PA (or vehicle
control) for 16 h in the absence or presence of 5 mmol/L D-glucose. *P< 0.05 vs. non–PA treated. E: L6 myotubes were incubated with 0.5 mmol/L PA
(or vehicle control) for 16 h in media containing or lacking 5 mmol/L D-glucose in the presence of different concentrations of 2-bromopalmitate as
indicated. Cells were then stimulated with insulin (20 nmol/L for 10 min) and resulting cell lysates used to immunoblot for native and phos-
phorylated Ser473 Akt, IkBa, and glyceraldehyde-3-phosphate dehydrogenase. All data are presented as mean 6 SEM from three independent
experiments.
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In contrast, a similar analysis from ﬁve obese animals on
the standard diet revealed that muscle Akt phosphoryla-
tion in response to insulin was severely blunted, consistent
with the signiﬁcant insulin resistance exhibited by these
animals (Fig. 7B). Strikingly, solei from ﬁve separate obese
animals fed 2DG all exhibited a signiﬁcant increase in Akt
phosphorylation (Fig. 7B). Analysis of IkBa abundance
revealed a signiﬁcant fall in soleus of obese animals on the
normal diet compared with those fed 2DG (Fig. 7C). In line
with this, the relative expression of muscle IL-6 and CINC-1
mRNA was signiﬁcantly lower in animals fed the 2DG-
supplemented diet (Fig. 7D).
DISCUSSION
A central tenet of the Randle hypothesis is that increased
provision and oxidation of FFAs in skeletal muscle
suppresses uptake and utilization of glucose as a conse-
quence of an increase in G6P that results in allosteric in-
hibition of key glycolytic enzymes (2). Our ﬁndings do not
support this premise, given that we observed a modest
reduction in the steady-state abundance of G6P when
muscle cells were rendered insulin resistant by PA in the
presence of glucose (Fig. 5A). Lipid infusion and clamp
studies also show that while raising plasma FFAs in
healthy individuals impairs glucose handling in skeletal
muscle, such disturbances are preceded by a fall rather
than an increase in intramuscular G6P as originally hy-
pothesized by Randle (30). Together, these observations
suggest that mechanisms other than a reduction in glyco-
lytic drive are likely to play a more prominent role in fatty
acid–induced insulin resistance in skeletal muscle.
Numerous studies suggest that accumulation of fatty
acid–derived DAG and ceramide are better predictors of
FIG. 5. Mitochondrial anaplerosis via sustained cellular pyruvate underpins the beneﬁcial metabolic effects of glucose withdrawal. A and B: In-
tracellular levels of G6P (Gluc 6-P) and glyceraldehyde 3-phosphate (glyceraldehyde 3-P) (A) and pyruvate (B) in L6 myotubes treated with 0.5
mmol/L PA (or vehicle control) for 16 h in the absence or presence of 5 mmol/L D-glucose as determined by LCMS analysis. C–F: L6 myotubes were
incubated with 0.5 mmol/L PA (or vehicle control) for 16 h in the absence or presence of 5 mmol/L D-glucose and different concentrations of PAC (C
and D) or aminooxyacetic acid (AOA) (E and F) as shown. After treatments, resulting cell lysates were subjected to SDS-PAGE and immuno-
blotted for total and phosphorylated Ser473 Akt, IkBa, and GAPDH as indicated. All data are presented as mean 6 SEM (n = 3). *P < 0.05 vs. cells
treated with D-glucose alone (A). *P < 0.05 vs. PA-treated cells in the presence of 5 mmol/L D-glucose (C–F). GAPDH, glyceraldehyde-3-phosphate
dehydrogenase.
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reduced insulin sensitivity (reviewed in 3,4). Indeed, studies
in rodents and cultured myotubes have demonstrated that
inhibiting enzymes involved in endogenous ceramide syn-
thesis (e.g., dihydroceramide desaturase-1 and serine
palmitoyl transferase) not only improves glucose homeo-
stasis but also restrains the insulin-desensitizing effects of
PA (6,31). Intriguingly, while suppressing de novo ceramide
synthesis from PA is insulin sensitizing in the short term,
sustained loss of serine palmitoyl transferase activity in
myotubes induces greater partitioning of PA toward DAG
biosynthesis, which then promotes insulin resistance via
PKC-mediated serine phosphorylation of IRS-1 (6). These
observations support a signiﬁcant role for DAG and
ceramides in fatty acid–induced insulin resistance. How-
ever, the current ﬁndings demonstrate that muscle cells
held in glucose-free media are protected against the dele-
terious effects of PA despite increases in intramyocellular
DAG and ceramide. These ﬁndings imply that the lipotoxic
effect of these lipids can be muted under certain circum-
stances and add to the current debate as to whether their
accumulation is inextricably linked to development of tis-
sue insulin resistance (32–34). Our studies indicate that
glucose or its metabolites may play a permissive role in the
pathogenic action of DAG and ceramide. Glucose availability/
metabolism may not only inﬂuence accumulation of select
DAG/ceramide species but also result in these lipids or
their signaling effectors being spatially segregated from
molecules mediating insulin and proinﬂammatory signal-
ing. The ﬁnding that cell-permeable ceramide impairs
Akt activation, irrespective of whether myotubes are held
in media containing glucose, supports the “segregation”
hypothesis. Moreover, we have previously demonstrated
that a critical feature underpinning inhibition of Akt in re-
sponse to ceramide is recruitment and retention of the
kinase within caveolin-enriched microdomains (CEMs)
(35). This targeting to CEMs is, in turn, dependent upon
caveolar recruitment of atypical PKCs, which are potently
activated by ceramide and which physically interact
with Akt and caveolin. Intriguingly, we ﬁnd that while PA
induces recruitment of atypical PKCs to CEMs in mus-
cle cells, this recruitment is substantially reduced in
PA-treated muscle cells that have be coincubated with
2DG (Supplementary Fig. 4). It is currently unclear how
2DG restrains PA-induced caveolar targeting of PKCs, but
the observation implies that the inability to relocalize
atypical PKCs to CEMs under glucopenic conditions may,
FIG. 6. Obese fa/fa Zucker rats maintained on a 2DG-supplemented diet gain less body weight and exhibit reduced plasma FFAs. Ten-week-old male
lean Fa/fa and obese fa/fa Zucker rats were maintained on an ad libitum standard chow diet (Con) or one supplemented with (0.4% w/w) 2DG for 28
days. Corresponding changes in body weight gain (A) and mean daily food intake (B) for each animal genotype/diet group were monitored twice
weekly and daily, respectively. Plasma glucose (C), triacylglycerol (TAG) (D), and total FFAs (E) were measured using blood specimens from
anesthetized rats after an overnight fast as described in RESEARCH DESIGN ANDMETHODS. Average epididymal fat pad weights from each animal genotype/
diet group are presented (F). All data are expressed as mean 6 SEM (n = 5/group). *P < 0.05, obese 2DG vs. obese control. ND, no difference.
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in part, explain how the inhibitory effects of PA on
Akt signaling are attenuated despite a prevailing intra-
myocellular increase in PA-derived ceramide.
It is plausible that the protective effect conferred by glu-
cose withdrawal/2DG supplementation against the proin-
ﬂammatory potential of PA may be linked to suppressing
effects that the fatty acid may have upon either reactive ox-
ygen species formation or signaling initiated via Toll-like re-
ceptor 4 (TLR4). However, we are able to discount the notion
that reactive oxygen species may be involved given that ap-
plication of antioxidants (N-acetylcysteine and vitamin C) did
not curtail PA-induced activation of the ERK-IKK signaling
axis (Supplementary Fig. 5). The involvement of TLR4 in our
cells can also be excluded, given that while LPS (a TLR4
ligand) induced IKK-directed signaling in bone marrow
dendritic cells, it had no observable effect on proinﬂammtory
NF-kB signaling in our muscle cells (Supplementary Fig. 6).
Mitochondrial dysfunction associated with FFA over-
load has been implicated in the pathogenesis of skeletal
muscle insulin resistance (36,37). Koves et al. (38)
demonstrated that increasing FFA oxidation by chronic
high-fat feeding or genetic obesity in mice imposes a major
substrate load on muscle’s oxidative machinery that even-
tually surpasses the respiratory drive for ATP synthesis.
Under these circumstances, FFAs undergo incomplete oxi-
dation resulting in accumulation of acylcarnitines, which
then promote insulin resistance by mechanisms that cur-
rently remain unclear (38). Accumulation of acylcarnitines
is, nonetheless, likely to be a secondary consequence of
reduced mitochondrial respiratory drive brought about by
FIG. 7. Obese Zucker rats maintained on a 2DG-supplemented diet exhibit improved skeletal muscle insulin sensitivity and reduced cytokine
expression. Ten-week-old lean (Fa/fa) and obese fa/fa Zucker rats were maintained on an ad libitum standard chow diet (CON) or one supple-
mented with 2DG (0.4% w/w) for 28 days. After overnight starvation, rats were anesthetized immediately prior to receiving an intravenous in-
jection of insulin (10 units/kg) for 5 min. Solei were isolated from each animal as described in RESEARCH DESIGN AND METHODS. Insulin signaling (total
Akt, phosphorylated Ser473Akt, and phosphorylated Thr308 Akt) was measured using lysates prepared from solei isolated 5 min after insulin in-
jection. (A: Lean animals, n = 3/group. B: Obese animals, n = 5/group.) For each animal, the phosphorylated Akt signal in each lane was normalized
to total Akt in that lane. These normalized values were then averaged from the 5 animals in each group to compare insulin-induced phosphorylation
of Akt (Ser473 and Thr308) in muscle of obese animals on the control diet versus that of obese animals on the 2DG diet (B, lower panel). C: Lysates
from non–insulin-stimulated solei from obese animals were used for immunoblot analysis of proinﬂammatory signaling (IkBa, glyceraldehyde-3-
phosphate dehydrogenase [GAPDH]) (B) (n = 5/group). Total RNA extracted from non–insulin-stimulated solei was used to determine IL-6 and
CINC-1 (D) relative to GAPDH mRNA expression by qPCR analysis (C) (n = 5/group). All values are presented as mean 6 SEM. *P < 0.05, obese
2DG vs. obese control (corresponding insulin treatment in B) or between indicated bar values.
SUBSTRATE OVERLOAD AND MITOCHONDRIAL DYSFUNCTION
3434 DIABETES, VOL. 62, OCTOBER 2013 diabetes.diabetesjournals.org
the impact that sustained fatty acid overload has upon
production of reactive oxygen species (39,40) and genes
encoding PGC-1a and respiratory chain components that,
together, will reduce the abundance, function, and in-
tegrity of mitochondria (12,13,16). Consistent with pre-
vious studies, we observe a signiﬁcant decline in PGC-1a
expression and mitochondrial respiration but, importantly,
demonstrate that these are a likely consequence of being
unable to deal with not only the carbon load born from PA
but also that originating from glucose. Moreover, the im-
proved insulin sensitivity and reduced proinﬂammatory
drive conferred by glucose withdrawal/glycolytic inhibi-
tion requires PA oxidation, since the metabolic beneﬁts
associated with glucose restriction are antagonized by
inhibiting mitochondrial PA uptake. Equally, it is note-
worthy that inhibiting fatty acid entry (and, hence, inﬂux
of fatty acid–derived carbon) into mitochondria when
glucose is available averts the insulin-desensitizing effect
associated with fatty acid overprovision (38). Together,
these observations imply that, irrespective of which met-
abolic fuel is available, as long as the total or combined
fuel load does not exceed mitochondrial oxidative capac-
ity and respiratory drive is maintained within a normal
threshold, the ﬁdelity with which insulin activates mole-
cules such as Akt is likely to be upheld.
Our work demonstrates that the ability to sustain PA ox-
idation and preserve insulin sensitivity when glucose avail-
ability is restricted depends on maintaining mitochondrial
anaplerosis. Inhibiting transaminases and pyruvate carbox-
ylase, which support anaplerotic generation of OAA, would
ultimately “run down” the TCA cycle with a concomitant
decline in respiratory activity and energy balance. The failure
to oxidize PA would then reinstate the insulin-desensitizing
and proinﬂammatory potential of PA. Since inhibiting mito-
chondrial anaplerosis will promote incomplete fatty acid
oxidation, we cannot exclude the possibility that impaired
insulin signaling seen under these conditions is attributable
to intramitochondrial acylcarnitine accumulation (38).
Reduced calorie intake has been shown to increase
PGC-1a expression, mitochondrial density, oxygen con-
sumption, and ATP production (41,42). These beneﬁcial
gains have been linked to sirtuin 1 (SIRT1), which
deacetylates PGC-1a, thereby enhancing transcription of
mitochondrial oxidative genes (43). AMP kinase (AMPK)
has been implicated as a SIRT1 activator (44), and very
recent work indicates that mice lacking AMPKa2 in skel-
etal muscle lose the insulin-sensitizing effect associated
with calorie restriction (45). Since glucose withdrawal
and 2DG supplementation are known to stimulate AMPK
and the activated kinase supports mitochondrial fatty acid
uptake by reducing cytosolic levels of malonyl CoA (via
phosphorylation/inhibition of acetyl CoA carboxylase), it is
plausible that the insulin-sensitizing and anti-inﬂammatory
effect associated with glucose withdrawal may involve
AMPK. In line with this possibility, we ﬁnd that muscle cells
in which AMPK expression/activity has been stably silenced
by ;90% (46) exhibit a compromised response to glucose
withdrawal in terms of repressing the PA effect upon Akt
activation and IkΒa loss (Supplementary Fig. 7). It is con-
ceivable that because myotubes still express some residual,
albeit small (;10%), measure of AMPK activity or SIRT1 is
activated via AMPK-independent mechanisms that this
may account for some of the salutary effects of glucose
withdrawal that remain in the AMPK-silenced myotubes.
However, while activation of SIRT1 by such mechanisms
cannot be excluded, two different deacetylase inhibitors
failed to suppress the protective effect conferred by glucose
withdrawal upon Akt and IkBa when myotubes were
overloaded with PA (Supplementary Fig. 8).
Since calorie restriction preserves mitochondrial func-
tion and tissue sensitivity to insulin, the development of
calorie restriction mimetics may offer an effective ap-
proach for combating insulin resistance and tissue in-
ﬂammation in conditions such as diabetes and obesity.
In accord with our cell-based observations and carbohydrate-
restriction studies (47), we demonstrate that dietary supple-
mentation of 2DG as a calorie restriction mimetic (48) in
an obese rodent model induces a dramatic reduction in cir-
culating FFAs that is associated with improved insulin-
dependent Akt phosphorylation and reduced inﬂammatory
tone in skeletal muscle. While we cannot exclude the
possibility that the reduction in plasma FFAs may be a
consequence of reduced lipolysis, the ﬁnding that epidid-
ymal fat pad mass was reduced signiﬁcantly in 2DG-fed
obese animals implies that the fall in circulating FFAs
may be linked to their greater oxidation in tissues such as
muscle. Whether these 2DG-driven responses in vivo are
a direct consequence of enhanced mitochondrial function
via, for example, the AMPK–PGC-1a axis is currently un-
clear, but testing this possibility more thoroughly is a ma-
jor goal of future work.
In summary, our report reveals that chronic over-
provision of PA induces a marked reduction in insulin
action and heightened proinﬂammatory signaling in skel-
etal muscle. These responses are associated with mito-
chondrial dysfunction that most likely stems from an
inability to match oxidative capacity to excess fuel supply.
Importantly, reducing the carbon load on mitochondria
by glucose withdrawal or glycolytic inhibition helps pre-
serve the ability to oxidize PA and restrains its insulin-
desensitizing and proinﬂammatory potential in muscle
cells. In support of this concept, a glucopenic diet prof-
fered to obese insulin-resistant animals induces beneﬁcial
gains in skeletal muscle insulin action and inﬂammatory
status. Together, these observations indicate that strate-
gies that maintain/improve mitochondrial oxidative capac-
ity may help limit metabolic dysfunction associated with
fatty acid overload in skeletal muscle.
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